Form 4 holding
Director
Venetian-1 Acquisition Corp.
- Security class
- Common Stock
- Shares / value
- 2,677,256
- Estimated value
- $10,709,024
- Report date
- 01 Nov 2024
- Price
- $4.00
- Ownership
- Indirect
Carl L. Gordon
Insider Reports History
- Reporting-owner location
- New York, NY
- Latest reporting-owner signature
-
/s/ Neil Lerner, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Carl L. Gordon
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 747,887
- Estimated value
- $8,107,095
- Report date
- 18 Feb 2025
- Price
- $10.84
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Terns Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 755,635
- Estimated value
- $7,556,350
- Report date
- 16 Jul 2024
- Price
- $10.00
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Common Stock
- Shares / value
- 1,513,664
- Estimated value
- $5,524,874
- Report date
- 30 Jan 2024
- Price
- $3.65
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Adicet Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 646,657
- Estimated value
- $924,720
- Report date
- 05 Jun 2024
- Price
- $1.43
- Ownership
- Indirect
Form 4 holding
Director
Keros Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 45,057
- Estimated value
- $799,761
- Report date
- 21 Nov 2025
- Price
- $17.75
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Adicet Bio, Inc.
- Security class
- Common Stock
- Shares / value
- 11,800
- Estimated value
- $16,874
- Report date
- 05 Jun 2024
- Price
- $1.43
- Ownership
- Direct
Form 4 holding
Director
Compass Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 09 Apr 2025
- Price
- $1.59
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Kinnate Biopharma Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 03 Apr 2024
- Price
- $2.59
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Theseus Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Feb 2024
- Price
- $3.05
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Theseus Pharmaceuticals, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 14 Feb 2024
- Price
- $3.05
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Compass Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 90,000
- Estimated value
- Report date
- 02 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adicet Bio, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 26,400
- Estimated value
- Report date
- 21 Aug 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Gemini Therapeutics, Inc. /DE
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 17,245
- Estimated value
- Report date
- 04 Oct 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Oric Pharmaceuticals, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 16,625
- Estimated value
- Report date
- 16 Jun 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 15,963
- Estimated value
- Report date
- 12 Sep 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Keros Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 10,500
- Estimated value
- Report date
- 04 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Terns Pharmaceuticals, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 4,676
- Estimated value
- Report date
- 01 Jul 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
ArriVent Biopharma, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 30 Jan 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Kinnate Biopharma Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 03 Apr 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series A Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Private Investments VII, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series B Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Private Investments VII, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MBX Biosciences, Inc.
- Security class
- Series C Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 16 Sep 2024
- Price
- Ownership
- By OrbiMed Genesis Master Fund, L.P.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Venetian-1 Acquisition Corp.
- Security class
- Simple Agreement for Future Equity
- Shares / value
- 0
- Estimated value
- Report date
- 01 Nov 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Carl L. Gordon
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 02 Jan 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2026, 16:32
- Role
- Director
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 21 Nov 2025
- Transactions
- 2
- Transaction value
- -$3,807,766
- Accepted by SEC
- 18 Dec 2025, 16:27
- Role
- Director
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 04 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 16:15
- Role
- Director
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 09 Apr 2025
- Transactions
- 1
- Transaction value
- -$5,678,571
- Accepted by SEC
- 11 Apr 2025, 19:37
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MBX
MBX Biosciences, Inc.
- Report period
- 14 Feb 2025
- Transactions
- 4
- Transaction value
- +$2,020,756
- Accepted by SEC
- 19 Feb 2025, 17:56
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 11 Feb 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Feb 2025, 17:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Lomond Therapeutics Holdings, Inc.
- Report period
- 01 Nov 2024
- Transactions
- 13
- Transaction value
- +$9,999,997
- Accepted by SEC
- 05 Nov 2024, 18:01
- Role
- Director
- Next action
- Open filing details
3
Lomond Therapeutics Holdings, Inc.
- Report period
- 01 Nov 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Nov 2024, 17:56
- Role
- Director
- Next action
- Open filing details
4
MBX
MBX Biosciences, Inc.
- Report period
- 16 Sep 2024
- Transactions
- 7
- Transaction value
- +$12,000,000
- Accepted by SEC
- 17 Sep 2024, 20:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MBX
MBX Biosciences, Inc.
- Report period
- 12 Sep 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Sep 2024, 17:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
MBX
MBX Biosciences, Inc.
- Report period
- 12 Sep 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 12 Sep 2024, 19:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 21 Aug 2024
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 23 Aug 2024, 16:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 13 Aug 2024
- Transactions
- 2
- Transaction value
- -$11,002,500
- Accepted by SEC
- 15 Aug 2024, 17:06
- Role
- Director
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 15 Jul 2024
- Transactions
- 6
- Transaction value
- -$561,640
- Accepted by SEC
- 17 Jul 2024, 20:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 01 Jul 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jul 2024, 18:36
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 10 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 18:04
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 05 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 16:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 30 May 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2024, 16:15
- Role
- Director
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 03 Apr 2024
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 05 Apr 2024, 16:39
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 14 Feb 2024
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2024, 16:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 09 Feb 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2024, 12:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
AVBP
ArriVent Biopharma, Inc.
- Report period
- 30 Jan 2024
- Transactions
- 10
- Transaction value
- +$7,999,992
- Accepted by SEC
- 31 Jan 2024, 16:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 25 Jan 2024
- Transactions
- 3
- Transaction value
- +$7,500,000
- Accepted by SEC
- 26 Jan 2024, 19:13
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
AVBP
ArriVent Biopharma, Inc.
- Report period
- 25 Jan 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 25 Jan 2024, 20:36
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 14 Aug 2023
- Transactions
- 8
- Transaction value
- $0
- Accepted by SEC
- 16 Aug 2023, 18:08
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 17 Jul 2023
- Transactions
- 2
- Transaction value
- +$1,463,793
- Accepted by SEC
- 19 Jul 2023, 16:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 27 Jun 2023
- Transactions
- 4
- Transaction value
- +$1,828,750
- Accepted by SEC
- 29 Jun 2023, 16:51
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 13 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2023, 17:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 12 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2023, 19:01
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 12 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2023, 18:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 06 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jun 2023, 16:48
- Role
- Director
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 01 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2023, 17:47
- Role
- Director
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 04 May 2023
- Transactions
- 5
- Transaction value
- +$4,086,235
- Accepted by SEC
- 08 May 2023, 17:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 28 Apr 2023
- Transactions
- 9
- Transaction value
- +$3,673,901
- Accepted by SEC
- 02 May 2023, 21:38
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 17 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 22 Feb 2023, 15:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 08 Feb 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Feb 2023, 15:28
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 23 Dec 2022
- Transactions
- 1
- Transaction value
- +$1,000,000
- Accepted by SEC
- 28 Dec 2022, 16:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 08 Nov 2022
- Transactions
- 1
- Transaction value
- +$1,290,420
- Accepted by SEC
- 10 Nov 2022, 15:38
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 07 Nov 2022
- Transactions
- 1
- Transaction value
- +$1,000,320
- Accepted by SEC
- 09 Nov 2022, 15:29
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 16 Aug 2022
- Transactions
- 6
- Transaction value
- +$8,929,800
- Accepted by SEC
- 18 Aug 2022, 16:50
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
TERN
Terns Pharmaceuticals, Inc.
- Report period
- 16 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2022, 21:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 13 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2022, 17:00
- Role
- Director
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 10 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 20:10
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 02 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:42
- Role
- Director
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 01 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2022, 16:25
- Role
- Director
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 11 May 2022
- Transactions
- 3
- Transaction value
- +$420,482
- Accepted by SEC
- 13 May 2022, 17:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 06 May 2022
- Transactions
- 3
- Transaction value
- +$197,252
- Accepted by SEC
- 10 May 2022, 18:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 18 Feb 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Feb 2022, 16:45
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Kinnate Biopharma Inc.
- Report period
- 11 Feb 2022
- Transactions
- 4
- Transaction value
- +$1,989,446
- Accepted by SEC
- 15 Feb 2022, 20:51
- Role
- Director
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 19 Jan 2022
- Transactions
- 3
- Transaction value
- +$1,578,717
- Accepted by SEC
- 21 Jan 2022, 18:22
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 11 Jan 2022
- Transactions
- 4
- Transaction value
- +$442,750
- Accepted by SEC
- 13 Jan 2022, 18:27
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACET
Adicet Bio, Inc.
- Report period
- 10 Dec 2021
- Transactions
- 1
- Transaction value
- +$2,999,990
- Accepted by SEC
- 14 Dec 2021, 18:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CMPX
Compass Therapeutics, Inc.
- Report period
- 04 Nov 2021
- Transactions
- 2
- Transaction value
- +$18,750,000
- Accepted by SEC
- 08 Nov 2021, 20:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 12 Oct 2021
- Transactions
- 7
- Transaction value
- +$10,000,000
- Accepted by SEC
- 14 Oct 2021, 17:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Theseus Pharmaceuticals, Inc.
- Report period
- 06 Oct 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Oct 2021, 19:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
Theseus Pharmaceuticals, Inc.
- Report period
- 06 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Oct 2021, 19:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
IRON
Gemini Therapeutics, Inc. /DE
- Report period
- 04 Oct 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 06 Oct 2021, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ORIC
Oric Pharmaceuticals, Inc.
- Report period
- 16 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2021, 19:44
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
KROS
Keros Therapeutics, Inc.
- Report period
- 01 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 03 Jun 2021, 17:27
- Role
- Director
- Next action
- Open filing details